The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease

Ya Zeng
Fudan University Shanghai Cancer Center

JianJiao Ni
Fudan University Shanghai Cancer Center

Fan Yu
Fudan University Shanghai Cancer Center

Yue Zhou
Fudan University Shanghai Cancer Center

Yang Zhao
Fudan University Shanghai Cancer Center

Shuyan Li
Fudan University Shanghai Cancer Center

Tiantian Guo
Fudan University Shanghai Cancer Center

Li Chu
Fudan University Shanghai Cancer Center

Xi Yang
Fudan University Shanghai Cancer Center

Xiao Chu
Fudan University Shanghai Cancer Center

XuWei Cai
Shanghai Jiao Tong University Affiliated Chest Hospital

Zhengfei ZHU (fuscczzf@163.com)
Fudan University Shanghai Cancer Center

https://orcid.org/0000-0001-7537-3619

Research

Keywords: Non-small cell lung cancer, Osimertinib, Oligo-residual disease, Local consolidative therapy

DOI: https://doi.org/10.21203/rs.3.rs-34341/v2
Abstract

Background: There was no study investigating real-world utilization and outcome of LCT in Osimertinib-treated NSCLC with oligo-residual disease. This study was to analyze the clinical value of local consolidative therapy (LCT) in Osimertinib-treated non-small cell lung cancer (NSCLC) patients with oligo-residual disease.

Methods: Patients receiving standard Osimertinib treatment and developing oligo-residual disease (five or fewer residual metastatic lesions) were retrospectively reviewed. Local therapies performed to the oligo-residual tumor lesions or primary lung site before Osimertinib treatment failure were considered as LCT.

Results: Of 108 patients recruited, first-line and second-line Osimertinib were administered in 25 and 83 patients, respectively, while LCT was performed in 14 patients. With a median follow-up of 43.6 months, 69 patients developed progressive disease. LCT significantly improved progression-free survival (PFS) (NR vs 12.8 months, p=0.01) and was independently associated with prolonged PFS (HR=0.29, 95%CI 0.12 to 0.68, p=0.004). Patients receiving LCT had a numerically longer overall survival (OS) (85.8 vs 77.1 months, p=0.58) and after adjusting for potentially confounding factors, LCT was associated with a non-significantly prolonged OS (HR=0.37, 95%CI 0.12-1.16, p=0.089). Pattern of failure analyses indicated that progressive disease developed at the originally existed oligo-residual lesions in 76.2% of the 63 patients who didn't receive LCT and had Osimertinib treatment failure. Of note, 7 (70%) of the 10 patients who had oligo-residual cranial disease but didn't receive LCT, developed more than five progressive lesions in the brain, which were no longer suitable for stereotactic radiosurgery.

Conclusion: Among Osimertinib-treated NSCLC patients having oligo-residual lesions, LCT could improve local control and significantly increase PFS, which need to be verified by further investigations.

Background

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR-sensitizing mutations [1]. There is an inevitable fact that, however, most patients would ultimately suffer disease progression [2-4]. Acquired EGFR ThrT790Met resistance mutation (T790M) appeared frequently in over half of patients who received first- or second-generation EGFR-TKIs [5-7].

Osimertinib is an oral, third-generation, irreversible EGFR-TKI that was proved to selectively inhibit both EGFR-TKI-sensitizing and EGFR T790M resistance mutations [8, 9]. Osimertinib has been the standard treatment for patients with metastatic T790M-positive NSCLC that progressed from EGFR-TKI treatment based on the AURA3 clinical trial with an impressive PFS extension [10-12]. It was also approved to be one of the first-line treatment options for EGFR-mutant NSCLC patients owing to the positive results from the FLAURA study, which demonstrated significant survival benefits in both PFS and OS [13, 14].
Accumulating evidence suggests that local consolidative therapy (LCT), such as surgery, radiotherapy and radiosurgery, could improve survival in highly selected patients with advanced NSCLC who have disease control after initially systemic therapy [15-19]. The landmark multicenter phase II study showed that LCT after effective systemic therapy significantly improved patients’ PFS and OS in oligometastatic NSCLC, when compared with conventional maintenance therapy [18, 19]. A retrospective study conducted by Xu et al, including synchronous oligometastatic EGFR-mutant NSCLC treated with first-generation EGFR TKIs, revealed that LCT administered to extracranial lesions and/or cranial lesions improved both PFS and OS. Meanwhile, in the prospective ATOM study, pre-emptive local therapy performed by stereotactic ablative radiotherapy, was feasible and prolonged PFS in first- or second-generation EGFR TKI treated NSCLC with oligo-residual disease. However, patients recruited in the studies mentioned above all received LCT when patients were treated with first- or second-generation EGFR-TKIs [15, 16]. It is well known that Osimertinib has higher potency against both cranial and extracranial tumor lesions, when compared with first- or second-generation EGFR TKIs. However, acquired resistance to Osimertinib was also inevitable [20, 21], and the clinical values of LCT in the era of Osimertinib for EGFR-mutant NSCLC remained unknown.

Our previous study found that 26.8% of EGFR-mutant NSCLC patients treated with Osimertinib were suitable for consolidative stereotactic body radiotherapy (SBRT) at the time of maximal response to Osimertinib [22]. However, there was no study investigating real-world utilization and outcome of LCT in Osimertinib-treated NSCLC with oligo-residual disease. Herein, we retrospectively examined the survival outcomes and patterns of treatment failure in Osimertinib-treated NSCLC patients with oligo-residual disease, receiving LCT or not in two academic centers, in order to determine the clinical values of LCT in such patients.

Methods

Patients

Patients with EGFR-mutant advanced NSCLC who received standard Osimertinib treatment in clinical trials or routine practice from January 2015 to December 2019 at Fudan University Shanghai Cancer Center and Shanghai Chest Hospital, were retrospectively reviewed. The inclusion criteria were as follows: 1) patients with pathologically diagnosed EGFR-mutant advanced NSCLC; 2) receiving standard Osimertinib treatment (first-line Osimertinib in untreated patients or second-line Osimertinib in pretreated T790M-positive patients); 3) having oligo-residual disease, which was defined according to the consensus of oligometastatic disease [23], during Osimertinib treatment with five or fewer residual metastatic lesions, excluding primary lung tumor (cranial and lymph node metastasis were allowed [16], and counted per lesion). The exclusion criteria included: 1) patients with a history of second malignancy; 2) patients with pleural or pericardial effusion; 3) patients without adequate follow-up information to determine the status of residual disease. The patients’ selection flowchart was shown in figure 1. Both Fudan University Shanghai Cancer Center and Shanghai Chest Hospital Institution Review Board
approved this study. Informed consent was waived by the institutional review boards because this was a retrospective study.

**Treatment and follow-up**

Patients received Osimertinib with a standard dosage of 80 mg/day as a sole systemic therapy were included in this study. LCT, including surgery, radiotherapy, and radiosurgery, were performed during Osimertinib treatment and to the primary lung tumors or the metastatic lesions, to the extracranial lesions or the intracranial metastases, in some of the patients. Generally, there would be a multidisciplinary team to decide whether the patient with oligo-residual disease needed to receive LCT. The final decision was at the discretion of the treating physician, as well as patient's preference.

Patients were generally followed up every two months. Chest computed tomography (CT) scans, CT scan or ultrasonography of abdominal and cervical regions, were routinely performed. Brain magnetic resonance imaging, positron emission tomography and bone scanning were not mandatory, and were performed at the discretion of the treatment physicians. Serial imaging of each patient was reviewed by a senior radiologist. Telephone calls were also implemented when necessary.

**Statistical Methods**

The overall survival (OS) was defined as the time from the date of diagnosis to death of any causes. Progression-free survival (PFS) was defined as the time from the date of the initiation of Osimertinib to the date of disease progression (by Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) or death of any causes. Patients who lived without disease progression were recorded as censored. OS and PFS were estimated by Kaplan-Meier method. Log-rank tests was used to compare the survival curves. Cox proportional hazards regressions were used to evaluate prognostic factors and calculate hazard ratios (HRs) for OS and PFS. P value less than 0.10 of clinical characteristics in univariate analyses and LCT were forcedly included in the multivariate analyses for OS owing to the small sample size. P value less than 0.05 (two sided) was considered statistically significant in this study.

**Results**

**Patients Characteristics**

There were 108 Osimertinib-treated advanced NSCLC patients recruited in this study, 14 of whom underwent LCT and the other 94 did not. There were 18.1% (17/94) of patients in non-LCT group and 8 patients in LCT group received Osimertinib as first-line treatment.
Local consolidative therapy was performed at a median time of 2.2 months (range, 1.5-10.0 months) after Osimertinib initiation. Three patients received surgical resection (brain=1, lung=2), 3 received cranial radiotherapy (stereotactic radiosurgery=1, whole brain radiotherapy=2) and the other 8 received ablative extracranial radiotherapy (lung=4, lymph node=3, bone=1). Among the 4 patients receiving irradiation to the lung, stereotactic body radiotherapy was performed in 3 patients. The clinical characteristics of the enrolled patients at the time of developing oligo-residual disease were presented in Table 1. Patients with less metastatic lesions ($p=0.018$), receiving first-line Osimertinib treatment ($p=0.003$) and without lung metastasis ($p=0.006$), were more likely to receive LCT.

Table 1. Disease characteristics of patients in non-LCT group and LCT group
|                           | no-LCT (94) | LCT (14) | p value |
|---------------------------|-------------|----------|---------|
| **Sex**                   |             |          | 0.63    |
| female                    | 54(57.4%)   | 9(64.3%) |         |
| male                      | 40(42.6%)   | 5(35.7%) |         |
| **Age (years)**           |             |          | 0.36    |
| Median (range)            | 62(38-83)   | 61(35-70)|         |
| **Smoking**               |             |          | 0.29    |
| no                        | 53(56.4%)   | 10(71.4%)|         |
| yes                       | 41(43.6%)   | 4(28.6%) |         |
| **T stage**               |             |          | 0.30    |
| T0-2                      | 78(83.0%)   | 13(92.9%)|         |
| T3-4                      | 16(17.0%)   | 2(7.1%)  |         |
| **N stage**               |             |          | 0.36    |
| N0                        | 48(51.1%)   | 9(64.3%) |         |
| N1-3                      | 46(48.9%)   | 5(35.7%) |         |
| **EGFR mutation**         |             |          | 0.49    |
| 19del                     | 45(47.9%)   | 7(50.0%) |         |
| L858R                     | 44(46.8%)   | 7(50.0%) |         |
| others                    | 5(5.3%)     | 0(0.0%)  |         |
| **No. mets**              |             |          | 0.018   |
| ≤2                        | 42(44.7%)   | 11(78.6%)|         |
| >2                        | 52(55.3%)   | 3(21.4%) |         |
| **No. mets. organs**      |             |          | 0.13    |
| ≤2                        | 86(91.5%)   | 14(100%) |         |
| >2                        | 8(8.5%)     | 0(0.0%)  |         |
| **Lung mets**             |             |          | 0.006   |
| no                        | 31(33.0%)   | 10(38.0%)|         |
| yes                       | 63(67.0%)   | 4(28.6%) |         |
| **Bone mets**             |             |          | 0.51    |
| no                        | 66(70.2%)   | 11(78.6%)|         |
| yes                       | 28(29.8%)   | 3(21.4%) |         |
| **Adrenal gland mets**    |             |          | 1.00    |
| no                        | 89(94.7%)   | 14(100%) |         |
| yes                       | 5(5.3%)     | 0(0.0%)  |         |
| **Brain mets**            |             |          | 0.07    |
| no                        | 64(68.1%)   | 6(42.9%) |         |
| yes                       | 30(31.9%)   | 8(57.1%) |         |
| **LN mets**               |             |          | 0.29    |
| no                        | 53(56.4%)   | 10(71.4%)|         |
| yes                       | 41(43.6%)   | 4(28.6%) |         |
| **Osimertinib**           |             |          | 0.003   |
| First-line                | 17(18.1%)   | 8(57.1%) |         |
| Second-line               | 77(81.9%)   | 6(42.9%) |         |

Abbreviation: LCT, local consolidative therapy; No, number; mets, metastasis; LN, lymph node.
Survival Outcomes

With a median follow-up of 43.6 months (range, 9.3-114.1 months), 69 patients developed progressive disease. The median progression-free survival (PFS) of the whole cohort was 14.0 months. The median PFS of patients in the non-LCT group was 12.8 months and the median PFS of patients in the LCT group was not yet reached. 1-year and 3-year PFS rate were 85.7%, 54.5% for patients in the LCT group and 53.7%, 16.6% for patients in the non-LCT group, respectively. The difference of PFS between two groups was statistically significant ($p=0.01$, HR=0.48, 95%CI 0.27 to 0.88, figure 2). Sex ($p=0.02$, HR=2.71, 95%CI 1.14-6.42), T stage ($p=0.01$, HR=1.30, 95%CI 1.06-1.59) and LCT ($p=0.004$, HR=0.29, 95%CI 0.12-0.68) were found to be independent predictors of PFS (shown in table 2).

| Table 2. Univariate and multivariate analysis of progression-free survival |
|---------------------------------|-----------------|-----------------|
| Univariate analysis            | Multivariate analysis |
| HR (95%CI)           | $p$ value | HR (95%CI)           | $p$ value |
| sex 1.79(1.12-2.89)  | 0.02     | 2.71(1.14-6.42)  | 0.02     |
| Age(years) 0.84(0.52-1.35)  | 0.47     | 0.59(0.24-1.44)  | 0.25     |
| smoking 1.61(0.99-2.59)  | 0.05     | <0.001           |          |
| T stage 0.35(0.20-0.63)  |          | 1.30(1.06-1.59)  | 0.01     |
| N stage 0.95(0.59-1.52)  | 0.82     |                  |          |
| EGFR mutation 0.94(0.62-1.44)  | 0.78     |                  |          |
| No. mets 0.92(0.57-1.47)  | 0.72     |                  |          |
| No. mets. organs 0.51(0.22-1.18)  | 0.12     |                  |          |
| lung mets 1.26(0.77-2.06)  | 0.37     |                  |          |
| bone mets 1.55(0.94-2.55)  | 0.08     |                  |          |
| adrenal gland mets 2.49(0.90-6.91)  | 0.08     |                  |          |
| brain mets 1.38(0.85-2.27)  | 0.19     |                  |          |
| LN mets 1.14(0.70-1.84)  | 0.60     |                  |          |
| Osimertinib 0.73(0.42-1.27)  | 0.27     |                  |          |
| LCT 0.48(0.27-0.88)  | 0.02     | 0.29(0.12-0.68)  | 0.004    |

Abbreviation: LCT, local consolidative therapy; No, number; mets, metastasis; LN, lymph node.

By the time of data-cutoff, 34 patients had died and the median OS was 77.1 months. The 1-, 3-, 5-year OS rate were 96.1%, 84.7% and 65.8%, in the entire cohort,
retrospectively. Patients receiving LCT had a numerically longer overall survival (OS) (85.8 vs 77.1 months, \( p=0.58 \), \textbf{figure 3}) and after adjusting potential confounding factors using Cox analyses, LCT was associated with a non-significantly prolonged OS (HR=0.37, 95%CI 0.12-1.16, \( p=0.089 \)) (shown in \textbf{table 3}).

\textbf{Table 3}. Univariate and multivariate analysis of overall survival

|                      | Univariate analysis |                  |                        | Multivariate analysis |                  |
|----------------------|---------------------|------------------|------------------------|-----------------------|------------------|
|                      | HR (95%CI)          | p value          |                        | HR (95%CI)            | p value          |
| sex                  | 1.78(0.90-3.52)     | 0.09             |                        | 1.30(0.62-2.73)       | 0.49             |
| age\(\text{years}\) | 0.66(0.33-1.32)     | 0.24             |                        | 1.30(0.62-2.73)       | 0.49             |
| smoking              | 1.45(0.71-2.89)     | 0.29             |                        | 1.30(0.62-2.73)       | 0.49             |
| T stage              | 0.27(0.12-0.57)     | 0.001            | 0.29(0.12-0.70)        | 0.006                |
| N stage              | 0.53(0.26-1.06)     | 0.07             | 0.55(0.26-1.16)        | 0.12                |
| EGFR mutation        | 1.25(0.67-2.34)     | 0.48             |                        | 1.30(0.62-2.73)       | 0.49             |
| No. mets             | 0.99(0.51-1.99)     | 0.99             |                        | 1.30(0.62-2.73)       | 0.49             |
| No. mets. organs     | 0.27(0.09-0.77)     | 0.02             | 1.01(0.27-4.30)        | 0.92                |
| lung mets            | 1.91(0.89-4.10)     | 0.09             | 2.0(0.72-6.99)         | 0.11                |
| bone mets            | 0.95(0.46-1.95)     | 0.89             |                        | 1.30(0.62-2.73)       | 0.49             |
| adrenal gland mets   | 1.94(0.46-8.17)     | 0.35             |                        | 1.30(0.62-2.73)       | 0.49             |
| brain mets           | 1.68(0.84-3.36)     | 0.14             |                        | 1.30(0.62-2.73)       | 0.49             |
| LN mets              | 2.05(1.02-4.10)     | 0.04             | 1.80(0.82-3.96)        | 0.15                |
| Osimertinib          | 1.07(0.31-3.71)     | 0.91             |                        | 1.30(0.62-2.73)       | 0.49             |
| LCT                  | 1.39(0.43-4.52)     | 0.58             | 0.37(0.12-1.16)        | 0.09                |

Abbreviation: LCT, local consolidative therapy; No, number; mets, metastasis; LN, lymph node.

\textbf{Patterns of treatment failure}

There were 67% (63/94) of patients in non-LCT group suffered Osimertinib treatment failure. Among them, 55.6% (35/63) of patients developed progressive disease only at the originally existed residual lesions (termed as original failure), 23.8% (15/63) of patients developed progressive disease only at distant new sites (termed as distant failure) and the rest (20.6%) patients developed progressive disease at both sites (termed as mixed failure). The most common sites of progressive disease were brain (21.6%), lung (16.2%), bone
Additionally, 27.0% (17/63) of patients with progressive disease received certain kind of salvage local therapy. Of note, 21 of the 30 patients with oligo-residual cranial lesions who didn’t receive LCT had progressive disease, 10 of whom developed progressive disease in the brain. Moreover, 7 of the 10 patients developed more than 5 progressive cranial lesions after Osimertinib treatment failure. Salvage brain radiotherapy were performed in 4 of the 7 patients, all of which were whole brain radiotherapy (WBRT).

There were totally 6 patients in the LCT group suffered failure. The failure patterns included brain (3/6 patients), bone (17%) and primary lesion (33%). 4 of 6 patients were original failure and the others were mixed failure. The details of the patterns of treatment failure for two groups were shown in figure 4.

Discussion

As far as we know, this was the first study that explored the real-world utilization and outcome of LCT in Osimertinib-treated NSCLC patients with oligo-residual disease. We found that LCT could significantly improve PFS in such patients. The pattern of failure analyses also favored administration of LCT instead of salvage local therapy, especially for those with oligo-residual cranial lesions, since deferring brain radiation may make these patients losing the opportunity of stereotactic radiosurgery (SRS), which has been demonstrated to have less neuro-toxicities compared with WBRT.

The rationale and feasibility of LCT in Osimertinib-treated NSCLC are validated in the current study. First, 55.6% (35/63) of patients in the non-LCT group developed progressive disease in the originally existed oligo-residual tumor sites, which was consistent with previous studies [24-26] and strongly indicated a potentially beneficial role of LCT. Second, 151 out of the 565 (26.7%) Osimertinib-treated NSCLC patients were identified to harboring oligo-residual disease in our study and it validated our previous result generated from Osimertinib-treated patients cohort with a smaller sample size, among which 26.8% of patients were found to be suitable for consolidative stereotactic body radiotherapy (SBRT) at the time of maximal response to Osimertinib[22]. Taken together, these data suggested that LCT, to part or all of the residual sites, could be performed in a considerable percentage of Osimertinib-treated NSCLC patients. In the current study, about 10% of the potential candidates received certain kind of LCT uneventfully, preliminarily demonstrated the feasibility and safety of LCT in such patients.

LCT to oligo-residual sites could significantly improve the PFS for EGFR-mutant NSCLC treated with EGFR-TKIs. Previous studies have found that LCT may prolong PFS in first- or second-generation EGFR-TKI treated NSCLC with oligometastatic disease by 4-6 months [15, 16, 27]. LCT, for the first-time, was shown to significantly prolong PFS in Osimertinib-treated NSCLC in our study. The median PFS for
patients treated with Osimertinib alone was 12.8 months in our study, which was within the reasonable range since patients receiving first-line or second-line Osimertinib were both included [11, 16]. Meanwhile, in the retrospective study which included patients with stage IV EGFR-mutant NSCLC who had oligometastatic disease during first-line EGFR-TKI therapy, Xu et al implied that only LCT to all sites can prolong PFS[16]. The interim results of the randomized phase III, open-label SINDAS trial showed that upfront stereotactic radiotherapy (SBRT) delivered to all of the oligo-metastatic sites in combination with first-line EGFR-TKI significantly improved both PFS and OS compared with EGFR-TKI alone [28]. In our study, LCT performed either to part of the residual sites or to all of the residual sites, analyzed together, were found to significantly decrease the risk of disease progression, when compared with those received no LCT (HR=0.48, 95%CI, 0.27 to 0.88). Due to the limited sample size, we could not further examine the separate role of LCT performed to part of the residual sites and those performed to all of the residual sites. Whether LCT to all oligometastatic sites could bring further survival benefit to patients with Osimertinib needs to be further investigated.

Patients in LCT group had a numerically longer survival than that of non-LCT group, but the improvement did not reach statistical significance in this study. There were a few studies implied that LCT could improve OS of patients treated with first generation EGFR-TKIs. Hu et al performed a study retrospectively recruiting 231 patients and found that LCT plus EGFR-TKI for patients with oligometastatic disease could significant improve OS compared with EGFR-TKI monotherapy alone (34 months vs 21 months) [15]. Another retrospective study conducted by Xu et al also revealed a statistical improvement of median OS by 10.1 months [16]. In the SINDAS trial, upfront SBRT combined with first-line EGFR-TKI significantly improved OS by 8.1 months compared with EGFR-TKI alone[28]. In the current study, however, the numerical improvement of OS for patients in LCT group did not reach statistical significance. The limited sample size of the study could be the main reason. Meanwhile, 27% patients in the non-LCT group received salvage local treatment when disease progressed after Osimertinib, which may be another confounding factor that may influence the OS result. As the Swiss cohort study discovered that salvage local therapy improved OS in Osimertinib-treated NSCLC with oligo-progressive disease [25]. Moreover, some of the patients in our study received LCT performed to part but not all of the residual sites and this may weaken the magnitude of clinical benefit of LCT in such patients, which had been demonstrated by the study conducted by Xu et al [16]. What we need to state was that the median OS was markedly longer in our study (LCT group vs. non-LCT group: 85.8 months vs. 77.1 months) than previous studies [16, 27]. For example, in the double-blind, randomized phase 3 FLAURA trail, a mean OS of 38.6 months were reported among patients receiving first-line Osimertinib [14]. One of the main reasons to explain the extraordinary long OS in our study was that most of the patients received second-line Osimertinib and OS was calculated from the diagnosis of advanced NSCLC. One previous study found that among patients who failed former first- or second-generation EGFR TKIs and acquired EGFR T790M mutation, Osimertinib treatment could induce a median OS of 50.4 months [29]. In addition, patients in this study were all harboring oligo-residual disease, whom are generally having more indolent disease and could have a relative longer overall survival [30]. Advanced NSCLC patients receiving curative treatment approaches for metastatic sites [31] had an obviously longer 5-year OS rate than those treated with palliative intent[32].
The optimal timing of local therapies for patients with EGFR-TKI treated NSCLC remains controversial [17, 18, 33]. We support the utilization of LCT to the oligo-residual disease rather than salvage local therapy to the oligo-progressive disease. Patients who received LCT to oligo-residual sites had less and smaller lesions [15, 16, 34] than patients who received salvage local therapy with oligo-progression disease. And the corresponding toxicities might be lower, which was partially supported by the phase II study exploring the efficacy of LCT to oligo-residual lesions after TKIs treatment[27]. Furthermore, due to the potent efficacy of Osimertinib in patients with brain metastasis[9], oligo-residual cranial disease at the maximal response of Osimertinib was not uncommon, which might be suitable for SRS. Whereas multiple progressive disease may develop in the central nervous system after Osimertinib treatment failure, where salvage WBRT is needed [33, 35]. And thus, deferring local cranial local therapy until Osimertinib treatment may make some patients lose the valuable opportunity of the less-toxic SRS. In a word, LCT may bring certain benefit for oligo-residual NSCLC patients treated with Osimertinib. While, there was an urgent need to recruit more patients to analyze whether patients with Osimertinib therapy could gain a statistical OS improvement from LCT in the future.

Given the small number of patients and the retrospective nature of the current study, there are some limitations. First, selection bias apparently existed which led to the imbalance of disease characteristics between the two groups, although Cox proportional hazards regressions were employed in order to reduce the possible bias. The results needed to be interpreted with caution. Second, LCT was performed to part of the oligo-residual disease, but not all of the oligo-residual disease, in most of the patients in the present study. This may also lead to the result that LCT failed to significantly improve OS. Lastly, as a retrospective study, we failed to obtain adequate data to analyze the toxicities of LCT.

**Conclusions**

LCT could significantly improve local control and PFS in Osimertinib-treated NSCLC patients with oligo-residual disease, which need to be verified by prospective study with a larger sample size.

**Abbreviations**

NSCLC, non-small cell lung cancer; LCT, local consolidative therapy; PFS, progression-free survival; OS, overall survival; EGFR-TKI, Epidermal growth factor receptor tyrosine kinase inhibitors; CT: Chest computed tomography; HRs, hazard ratios; SRS, stereotactic radiosurgery; SBRT, stereotactic body radiotherapy; WBRT, whole brain radiotherapy. Mets, metastasis; No, number; LN, lymph node.

**Declarations**

**Ethics approval and consent to participate:** Both involved institution committees approved this study (Ethics Committee of Fudan University Shanghai Cancer Center, Ethics Committee of Shanghai Chest Hospital). Both ethics committee did not permit data-sharing. Informed consent was waived by the institutional review boards because this was a retrospective study.
Consent for publication: Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by Shanghai Science and Technology Committee (Grant No.19411965900).

Authors’ contributions

ZZF, CXW, NJJ contributed to the conception and designed the manuscript. ZY, YF, ZY, ZY, LSY, GTT collected and analyzed the patient data. ZZF, CXW, NJJ, CL, YX, CX collected the patients’ data. ZY, NJJ were the major contributors in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements: This work was supported by Shanghai Science and Technology Committee (Grant No.19411965900).

References

1. D Planchard, S Popat, K Kerr et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29: iv192–iv237.

2. Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015;26: 1883-1889.

3. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology 2011;12: 735-742.

4. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11.

5. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. N Engl J Med 2005;352: 786-792.

6. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17: 1616-1622.

7. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19: 2240-2247.
8. Cross DA, Ashton SE, Ghiorghi S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4: 1046-1061.

9. Wu YL, Ahn MJ, Garassino MC, et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol 2018;36: 2702-2709.

10. Goss G, Tsai C-M, Shepherd FA, et al Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology 2016;17: 1643-1652.

11. Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol 2017;35: 1288-1296.

12. Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med. 2016;376(7): 629-640.

13. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med 2018;378: 113-125.

14. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020;382: 41-50.

15. Hu F, Xu J, Zhang B, et al. Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations. Clinical Lung Cancer 2018;20(1): e81-e90.

16. Xu Q, Zhou F, Liu H, et al. Considative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. J Thorac Oncol. 2018;13: 1383-1392.

17. Weickhardt AJ, Scheier B, Burke JM, et al. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer. J Thorac Oncol. 2012;7: 1807–1814.

18. Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17: 1672-1682.

19. Gomez DR, Tang C, Zhang J, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional,Phase II, Randomized Study. J Clin Oncol 2019;37: 1558-1565.

20. Hayakawa D, Takahashi F, Mitsuishi Y, et al. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Thorac Cancer 2020;11: 140-149.

21. Mu Y, Hao X, Xing P, et al. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. J Cancer Res Clin Oncol. 2020;146(9):2427-2433.
22. Guo T, Ni J, Yang X, et al. Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2020;107: 62-71.

23. Dingemans AC, Hendriks LEL, Berghmans T, et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol 2019;14: 2109-2119.

24. Al-Halabi H, Sayegh K, Digamurthy SR, et al. Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. J Thorac Oncol 2015;10: 1601–1607.

25. Schmid S, Klingbiel D, Aeppli S, et al. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019;130: 149–155.

26. Yang JJ, Chen HJ, Yan HH, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013;79: 33-39.

27. Chan OSH, Lam KC, Li JYC, et al. ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases of NSCLC After EGFR TKI. Lung Cancer 2020;142: 41-46.

28. Wang X, Zeng M. First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332). J Clin Oncol 2020;38: 9508-9508.

29. Wang S, Yan B, Zhang Y, et al. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. Int J Cancer 2019;144: 2880-2886.

30. Parikh RB, Cronin AM, Kozono DE, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014;15: 880-887.

31. Luketich JD, Martini N, Ginsberg RJ, et al. Successful treatment of solitary extracranial metastases from non-small cell lung cancer. Ann Thoracic Surg 1995;60: 1609–1611.

32. Johnson KK, Rosen JE, Salazar MC, et al. Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer. Ann Thorac Surg 2016;102: 1166-1171.

33. Miyawaki E, Kenmotsu H, Mori K, et al. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. Int J Radiation Oncol Biol Phys 2019.

34. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for LimitedMetastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4: e173501.

35. Lee JH, Chen HY, Hsu FM, et al. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. The Oncologist 2019;24: e1417–e1425.

Figures
1311 Osimertinib-treated patients from January 2015 to December 2019 at two institutions

746 patients excluded:
- 701 patients with unknown EGFR mutation status
- 45 patients EGFR mutation negative

565 patients with standard Osimertinib treatment

414 patients excluded:
- 52 patients with pleura or pericardial effusion;
- 35 patients without regular follow-up during Osimertinib treatment;
- 327 patients with more than 5 residual metastatic lesions.

151 patients who received standard Osimertinib treatment and developed oligo-residual disease

43 patients excluded:
- 35 Patients with a history of second malignancy;
- 8 Patients who lost follow-up

14 patients with local consolidative therapy (LCT group)

94 patients without local consolidative therapy (non-LCT group)

**Figure 1**

Patients enrollment flowchart.
Figure 2

Progression-free survival (PFS) curves of LCT group and non-LCT group. The median PFS of LCT group was not reached and 12.8 months for patients in non-LCT group. LCT: local consolidative therapy.
Overall survival (OS) curves of LCT group and non-LCT group. The median OS were respectively 85.8 months and 77.1 months for patients in LCT group and non-LCT group. LCT: local consolidative therapy.
Figure 4

The details of failure patterns of two groups. LCT: local consolidative therapy.